CytoDyn Cleared to Start Phase 2 Basket Trial of Leronlimab for Multiple Solid Cancers

CytoDyn Cleared to Start Phase 2 Basket Trial of Leronlimab for Multiple Solid Cancers
CytoDyn has been cleared by an institutional review board to start a Phase 2 trial testing its investigational therapy leronlimab (PRO 140) to treat about 22 different solid cancers, including ovarian cancer. Leronlimab is an antibody that blocks C-C motif chemokine receptor 5 (CCR5), a protein present in high levels in several cancers. CCR5 acts like a navigation system for tumor cells which allows them to migrate to other areas of the body (metastasize). The upcoming Phase 2 trial will be a basket trial, a type of clinical trial where a single investigational therapy or therapy combinations will be evaluated across multiple cancer populations. It will include patients with cancers of the ovary, brain, throat, lung, stomach, colon, breast, testicle, uterus, pancreas, bladder, among others. The primary endpoint of the trial will be the length of time that patients live without disease worsening. “Our current basket trial focuses on method of action (MOA) rather than a specific cancer type,” Nader Pourhassan, PhD, president and CEO of CytoDyn, said in a
Subscribe or to access all post and page content.